HYPERTENSION IS A MAJOR RISK

Similar documents
Trends in Prevalence, Awareness, Management, and Control of Hypertension Among United States Adults, 1999 to 2010

DATA FROM THE THIRD NAtional

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

Hypertension awareness, treatment, and control

THE PREVALENCE OF OVERweight

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex

The New England Journal of Medicine

YOUNG ADULT MEN AND MIDDLEaged

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths

HIGH BLOOD PRESSURE IS AN EStablished

A n aly tical m e t h o d s

Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S.

Hypertension is an important public health challenge in

Why Do We Treat Obesity? Epidemiology

Hypertension in Adults Across the Age Spectrum

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Hypertension. Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008

A Needs Assessment of Hypertension in Georgia

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

Chapter 1: CKD in the General Population

This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both

Cardiovascular disease (CVD), including stroke, is the

ORIGINAL INVESTIGATION. Sex-Specific Trends in Midlife Coronary Heart Disease Risk and Prevalence

The prevalence of obesity has increased markedly in

ARTICLE. Prevalence of Diabetes and Impaired Fasting Glucose Levels Among US Adolescents. National Health and Nutrition Examination Survey,

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Chronic kidney disease (CKD) has received

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

The presence of cardiovascular disease risk factors, clinical

Antihypertensive Drug Therapy and Survival by Treatment Status in a National Survey

Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients

The incidence and prevalence of hypertension

Hypertension affects 65 million adult Americans 1 and is

The prevalence of hypertension in a representative

Pooja Bansil, MPH; Elena V. Kuklina, MD, PhD; Robert K. Merritt, MA; Paula W. Yoon, ScD, MPH

The New England Journal of Medicine

The problem of uncontrolled hypertension

Hypertension and the SPRINT Trial: Is Lower Better

Research Article Prevalence and Trends of Adult Obesity in the US,

Type 2 diabetes mellitus with hypertension at primary healthcare level in Malaysia: are they managed according to guidelines?

Patterns of adolescent smoking initiation rates by ethnicity and sex

Potential U.S. Population Impact of the 2017 American College of Cardiology/ American Heart Association High Blood Pressure Guideline

Population studies are essential to assess the distribution. Distribution of Blood Pressure and Hypertension in Canada and the United States

T. Suithichaiyakul Cardiomed Chula

Association of Hypertension Treatment and Control With All-Cause and Cardiovascular Disease Mortality Among US Adults With Hypertension

Diastolic hypertension, defined as a diastolic blood pressure

Multiple clinical and observational studies in the elderly

Diet Quality and History of Gestational Diabetes

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Judy Kruger, PhD, MS, Deborah A. Galuska, PhD, MPH, Mary K. Serdula, MD, MPH, Deborah A. Jones, PhD

Progress in the Control of Childhood Obesity

Approximately 30% of adults in the United States have

47 Hypertension in Elderly

Diabetes Care Publish Ahead of Print, published online February 25, 2010

Chapter 2: Identification and Care of Patients With CKD

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines

Cedars Sinai Diabetes. Michael A. Weber

NBER WORKING PAPER SERIES THE IMPACT OF ANTIHYPERTENSIVE DRUGS ON THE NUMBER AND RISK OF DEATH, STROKE AND MYOCARDIAL INFARCTION IN THE UNITED STATES

Overweight/Obesity & Physical Inactivity. Healthy Kansans 2010 Steering Committee Meeting April 22, 2005

Hypertension is a powerful risk factor for fatal and

Diabetes and Decline in Heart Disease Mortality in US Adults JAMA. 1999;281:

Vital Signs: Prevalence, Treatment, and Control of Hypertension United States, and

Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia

OVERALL TRENDS IN OBESITY

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!

Since the early 1900s, cardiovascular disease has been. Assessment of the Treatment of Hypertension in a University HMO Ambulatory Clinic

Controlling Hypertension in Primary Care: Hitting a moving target?

Prediction of Cardiovascular Death in Racial/Ethnic Minorities Using Framingham Risk Factors

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Blood Pressure Control in Hypertensive Patients, Iran: A Cross-Sectional Study

Prevalence of Hypertension in Semi-Urban area of Nepal

Obesity and Control. Body Mass Index (BMI) and Sedentary Time in Adults

Firenze 22 settembre 2007

Biostats Final Project Fall 2002 Dr. Chang Claire Pothier, Michael O'Connor, Carrie Longano, Jodi Zimmerman - CSU

This chapter examines the sociodemographic

Prevalence, awareness of hypertension in rural areas of Kurnool

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

We have recently published blood pressure (BP) percentiles

Chapter 1: CKD in the General Population

Chapter 2: Identification and Care of Patients With CKD

Using the New Hypertension Guidelines

Healthy Montgomery Obesity Work Group Montgomery County Obesity Profile July 19, 2012

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,

Comparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, : Review

Hypertension is an important global public

Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey

Research. A comparison of blood pressure measurement over a sleeved arm versus a bare arm. The measurement of blood pressure is one of the

KEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.

2009 Shattuck Lecture

USRDS UNITED STATES RENAL DATA SYSTEM

ORIGINAL INVESTIGATION. Awareness, Knowledge, and Attitudes of Older Americans About High Blood Pressure

ORIGINAL INVESTIGATION. Prevalence of High Blood Pressure and Elevated Serum Creatinine Level in the United States

a Department of Internal Medicine, National Taiwan University Hospital and Received 12 March 2007 Revised 10 October 2007 Accepted 23 October 2007

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Hypertension in the very old. Objectives: Clinical Perspective

Are hypertensive elderly patients treated differently?

Transcription:

ORIGINAL CONTRIBUTION Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000 Ihab Hajjar, MD, MS Theodore A. Kotchen, MD Context Prior analyses of National Health and Nutrition Examination Survey (NHANES) data through 1991 have suggested that hypertension prevalence is declining, but more recent self-reported rates of hypertension suggest that the rate is increasing. Objective To describe trends in the prevalence, awareness, treatment, and control of hypertension in the United States using NHANES data. Design, Setting, and Participants Survey using a stratified multistage probability sample of the civilian noninstitutionalized population. The most recent NHANES survey, conducted in 1999-2000 (n=5448), was compared with the 2 phases of NHANES III conducted in 1988-1991 (n=9901) and 1991-1994 (n=9717). Individuals aged 18 years or older were included in this analysis. Main Outcome Measures Hypertension, defined as a measured blood pressure of 140/90 mm Hg or greater or reported use of antihypertensive medications. Hypertension awareness and treatment were assessed with standardized questions. Hypertension control was defined as treatment with antihypertensive medication and a measured blood pressure of less than 140/90 mm Hg. Results In 1999-2000, 28.7% of NHANES participants had hypertension, an increase of 3.7% (95% confidence interval [CI], 0%-8.3%) from 1988-1991. Hypertension prevalence was highest in non-hispanic blacks (33.5%), increased with age (65.4% among those aged 60 years), and tended to be higher in women (30.1%). In a multiple regression analysis, increasing age, increasing body mass index, and non- Hispanic black race/ethnicity were independently associated with increased rates of hypertension. Overall, in 1999-2000, 68.9% were aware of their hypertension (nonsignificant decline of 0.3%; 95% CI, 4.2% to 3.6%), 58.4% were treated (increase of 6.0%; 95% CI, 1.2%-10.8%), and hypertension was controlled in 31.0% (increase of 6.4%; 95% CI, 1.6%-11.2%). Women, Mexican Americans, and those aged 60 years or older had significantly lower rates of control compared with men, younger individuals, and non-hispanic whites. Conclusions Contrary to earlier reports, hypertension prevalence is increasing in the United States. Hypertension control rates, although improving, continue to be low. Programs targeting hypertension prevention and treatment are of utmost importance. JAMA. 2003;290:199-206 www.jama.com HYPERTENSION IS A MAJOR RISK factor for cardiovascular disease morbidity and mortality. 1-3 The National Health and Nutrition Examination Survey (NHANES), conducted by the National Center for Health Statistics, provides periodic information on the health of the US population. Based on earlier analyses of NHANES data, with the possible exception of black men aged 50 years or older, hypertension prevalence has decreased between 1960 and 1991. 4 In addition, during this time, the entire population-based blood pressure (BP) distribution shifted downward. 5 In apparent contrast with these favorable trends, according to the Behavioral Risk Factor Surveillance System (BRFSS), self-reported hypertension was 24.9% in 1999 compared with 22.9% in 1991. 6 This increase may represent an increase in awareness, but because the BRFSS does not include BP measurements, the current hypertension prevalence rate in the community is not known. Despite the overwhelming evidence that hypertension control is associated with a significant reduction in cardiovascular events, 7-9 less than 25% of the US population with hypertension had their BP controlled in 1988-1991. 10 The goal of the US Department of Health and Human Services that 50% of Americans with hypertension have their BP controlled by the year 2000 was not met, and this goal has been reestablished to be achieved by 2010. 11,12 Recent trends in hypertension control in the US population are not known. We analyzed NHANES data to determine trends in the prevalence, awareness, treatment, and control of hyper- Author Affiliations: Division of Geriatrics, Department of Medicine, Palmetto Health Richland, University of South Carolina, Columbia (Dr Hajjar); Departments of Medicine and Epidemiology, Medical College of Wisconsin, Milwaukee (Dr Kotchen). Corresponding Author and Reprints: Ihab Hajjar, MD, MS, Division of Geriatrics, Department of Medicine, Palmetto Health Alliance, University of South Carolina, 9 Medical Park, Suite 230, Columbia, SC 29203 (e-mail: ihab.hajjar@palmettohealth.org). 2003 American Medical Association. All rights reserved. (Reprinted) JAMA, July 9, 2003 Vol 290, No. 2 199

tension in the United States between 1988 and 2000. METHODS NHANES is a stratified multistage probability sample of the civilian noninstitutionalized US population. The third NHANES was conducted in 2 phases between 1988 and 1994; the first phase in 1988-1991 and the second phase in 1991-1994. 13 The most recent NHANES was conducted in 1999 and 2000. 12 Although each of the surveys has an overall similar design, the 1999-2000 survey has a smaller sample size and is the first part of the continuous NHANES. 14 This may lead to a higher SE for variables measured in the 1999-2000 survey. 15 All participants provided informed consent and the data were approved by the Centers for Disease Control and Prevention Institutional Review Board as ensuring confidentiality. 14 For this analysis, we included data on all participants aged 18 years or older. This includes age, sex, and selfassigned race/ethnicity (non-hispanic whites, non-hispanic blacks, Mexican Americans, and other racial groups, including non Mexican American Hispanic whites and blacks). In addition, body mass index (BMI; calculated as weight in kilograms divided by the square of height in meters) and BP measurements and hypertension and diabetes mellitus history were included. A certified operator performed BP measurements using a mercury sphygmomanometer and a standardized procedure in each survey during the home interview and during the physical examination at home or at a mobile examination center. A cuff size appropriate for the participant s arm circumference was used. Quality control was ensured by operator recertification, procedural checklists, and data review. 16,17 In the 1999-2000 phase, 9.7% had fewer than 3 BP readings compared with 0.5% in the 1991-1994 phase and 0.4% in the 1988-1991 phase (P.01). A small ( 1%) and similar number of participants in all 3 phases reported that they had never had a BP measurement. Those interviewed but not examined were not included in the analysis (n=1076 in 1988-1991, n=790 in 1991-1994, and n=472 in 1999-2000). Each survey used similar questions for hypertension history. We considered a participant to be hypertensive if the average systolic BP (SBP) was 140 mm Hg or higher or the average diastolic BP (DBP) was 90 mm Hg or higher or if the participant was currently receiving antihypertensive medications. The same criteria were used for both diabetic and nondiabetic participants. Participants were considered to be aware of their hypertension if they answered yes to the interview question Have you ever been told by a doctor or health professional that you had hypertension, also called high blood pressure? Participants were considered to be treated if they answered yes to the interview question Because of your high blood pressure/ hypertension are you now taking prescribed medicine? Participants were considered to have their hypertension controlled if they were receiving antihypertensive medications and their average SBP was less than 140 mm Hg and average DBP was less than 90 mm Hg. A separate control variable was defined for diabetic participants. Participants were considered diabetic if they answered yes to at least 1 of these interview questions: Have you ever been told by a doctor that you have diabetes or sugar diabetes? or Are you now taking insulin? or Are you now taking diabetes pills to lower blood sugar? Diabetic participants were considered to have controlled hypertension if they were receiving antihypertensive medication and their mean BP was below the recommended target. Because of the change in recommendations between 1988 and 2000 to a lower target BP in diabetic individuals, we defined control in those with diabetes based on 2 criteria for BP: a mean SBP of less than 140 mm Hg and a mean DBP of less than 90 mm Hg, and a mean SBP of less than 130 mm Hg and a mean DBP of less than 85 mm Hg. 18 Each survey oversampled African Americans, Mexican Americans, and individuals aged 60 years or older. 14,19 To adjust for oversampling, special sampling weights were included in our analysis. These weights also adjusted for nonresponse bias and poststratification population totals. 20 To obtain estimates of the sampling errors, a Taylor linear approximation method and jackknife 1 procedures were used in each of the 3 surveys. 19,21,22 In consideration of the complex sample design, SAS version 8.02 (SURVEYMEANS, SURVEYREG) 23 and WesVar version 4.2 (Westat Inc, Rockville, Md) software were used. For statistical analyses of differences over time, data from the 1999-2000 survey were compared with 1988-1991 data rather than the entire NHANES III survey to provide more comparable sample sizes. The test for a linear trend over the 3 phases of the NHANES survey is the same as for a comparison of the first and last surveys. In accordance with the Joint Policy on Variance Estimation, estimates with a coefficient of variation larger than 0.30 or a sample size smaller than the recommended size for the design effect or the estimated proportion were considered unreliable. 15,24 Hypothesis testing was not performed on unreliable estimates. Age adjustment and population estimates were calculated using the standard 2000 US population estimates, with a population breakdown by 10-year increments. 25 The following age groups were used in this analysis in accordance with the 1999-2000 survey s analytic guidelines: 18-39 years, 40-59 years, and 60 years or older. 15 Tests for trend were performed using the t test for comparisons of weighted means (to adjust for sampling weights) between the 1988-1991 and 1999-2000 data. We used a conservative approach for statistical significance ( =.01) to help account for multiple comparisons. Multiple regression analysis was performed with hypertension as the outcome variable and age, sex, race/ethnicity, and BMI as predictors to calculate the independent association between the predictors and the outcome variables. This analysis was performed separately for each of the 3 phases. Results were nonstandardized. We used SAS SURVEYREG and Wes- 200 JAMA, July 9, 2003 Vol 290, No. 2 (Reprinted) 2003 American Medical Association. All rights reserved.

Var to account for survey design and sampling weights. The increase in hypertension prevalence attributable to BMI was determined by running the regression model and performing analysis of covariance to determine the independent associations between hypertension and BMI. RESULTS TABLE 1 provides the sample sizes by sex, race/ethnicity, and age. Average age of the participants, sex, racial/ethnic distribution, and mean SBP and DBP were similar in each of the 3 phases (TABLE 2.) Participants in 1999-2000 had a higher BMI (P.001) and a higher prevalence of diabetes than in 1988-1991 (P.001). In 1999-2000, the age-adjusted hypertension prevalence was 28.7% (TABLE 3), an absolute increase of 3.7% compared with 1988-1991. Non-Hispanic blacks had the highest prevalence of hypertension (P=.04 for 1988-1991, P=.001 for 1991-1994, and P=.01 for 1999-2000) and Mexican Americans had the lowest rates (P.001 for all 3) in all 3 surveys, and rates for all racial/ethnic groups tended to increase between 1988 and 2000. Hypertension prevalence increased to a greater extent in individuals aged 60 years or older than in younger individuals. Non-Hispanic black women had the greatest increase in hypertension prevalence and non-hispanic white men had the smallest (7.2% of non-hispanic black women vs 1.0% of non-hispanic white men). Hypertension prevalence in all age, sex, and race/ethnicity groups is shown in FIGURE 1. Based on the 1999-2000 survey, among both men and women, hypertension prevalence in those aged 40 to 59 years and those aged 60 years or older was higher in non- Hispanic blacks than in non-hispanic whites and Mexican Americans. A multiple regression analysis was carried out to assess the independent association of hypertension prevalence with demographics and BMI, considered simultaneously (TABLE 4). In each of the 3 surveys, hypertension was associated with increasing age (P.001), non-hispanic black race/ethnicity (P.001), and higher BMI (P.001). Table 1. No. of Participants by, Race/Ethnicity, and Age in 3 NHANES Phases 1988-1991 (n = 9901) 1991-1994 (n = 9717) 1999-2000 (n = 5448) Men 4781 4083 2337 Non-Hispanic white 2244 1585 1131 18-39 628 417 638 40-59 564 382 289 60 1052 783 474 Non-Hispanic black 1190 1246 485 18-39 558 635 205 40-59 323 322 138 60 309 289 142 Mexican American 1347 1252 721 18-39 733 664 329 40-59 302 291 168 60 312 297 224 Women 4812 5187 2619 Non-Hispanic white 2260 2283 1222 18-39 656 670 465 40-59 513 562 278 60 1091 1051 479 Non-Hispanic black 1270 1632 564 18-39 601 870 247 40-59 318 458 151 60 358 304 166 Mexican American 1282 1272 833 18-39 686 703 407 40-59 311 285 203 60 285 284 223 Abbreviation: NHANES, National Health and Nutrition Examination Survey. Table 2. Characteristics of Participants in 3 NHANES Phases* Characteristics 1988-1991 (n = 9901) 1991-1994 (n = 9717) 1999-2000 (n = 5448) Interviewed but not examined, No. (%) 1076 (11) 790 (8) 472 (9) Age, mean (SE), y 43.4 (0.4) 44.1 (0.6) 44.0 (0.3) Age group, y 18-39 40 43 42 40-59 25 25 25 60 35 32 34 Women 52 52 52 Non-Hispanic white 77 75 70 Non-Hispanic black 11 11 11 Mexican American 5 5 7 Other 7 9 12 Body mass index, mean (SE) 26.1 (0.1) 26.7 (0.1) 27.8 (0.1) Never had blood pressure checked 0.6 0.3 0.5 Blood pressure, mean (SE), mm Hg Systolic 122.0 (0.5) 122.1 (0.4) 122.9 (0.4) Diastolic 73.3 (0.2) 74.4 (0.3) 72.1 (0.2) Diabetes mellitus 5 5 7 Abbreviation: NHANES, National Health and Nutrition Examination Survey. *Data are weighted to the US population and expressed as percentages unless otherwise noted. Body mass index was calculated as weight in kilograms divided by the square of height in meters. P.001 for the difference between the 1988-1991 and 1999-2000 surveys. 2003 American Medical Association. All rights reserved. (Reprinted) JAMA, July 9, 2003 Vol 290, No. 2 201

Hypertension was not associated with sex (P=.37) in the regression analysis. In all 3 surveys, demographic characteristics and BMI accounted for 30% to 31% (age accounted for 26%, non- Hispanic black race/ethnicity for 0.4%, and BMI for 5%) of the hypertension prevalence. Table 3. Age-Specific and Age-Adjusted Prevalence of Hypertension by and Race/Ethnicity in the US Population, 1988-2000* Figure 1. Hypertension Prevalence by Age and Race/Ethnicity in Men and Women Hypertension Prevalence, % 100 80 60 40 20 0 Men Non-Hispanic White Non-Hispanic Black Mexican American 18-39 40-59 60 Prevalence, % (SE) Change, 1988 to 2000 Characteristics 1988-1991 1991-1994 1999-2000 % (95% CI) P Value Age-Specific Data 18-39 5.1 (0.6) 6.1 (0.6) 7.2 (1.1) 2.1 ( 0.3 to 4.5).05 40-59 27.0 (1.4) 24.3 (2.2) 30.1 (1.8) 3.1 ( 1.4 to 7.6).09 60 57.9 (2.0) 60.1 (1.1) 65.4 (1.6) 7.5 (2.4 to 12.5).002 Age-Adjusted (to 2000 US Population) Data Overall 25.0 (1.5) 25.0 (1.7) 28.7 (1.8) 3.7 (0 to 8.3).02 Men 24.9 (2.1) 23.9 (2.6) 27.1 (2.7) 2.2 ( 4.5 to 8.9).26 Women 24.5 (1.7) 26.0 (1.8) 30.1 (2.4) 5.6 (0 to 11.4).03 Non-Hispanic white 25.9 (1.8) 25.6 (2.1) 28.9 (2.3) 3.1 ( 2.7 to 8.7).14 Non-Hispanic black 28.9 (2.2) 32.5 (2.1) 33.5 (3.2) 4.6 ( 3 to 12.2).12 Mexican American 17.2 (1.6) 17.8 (2.0) 20.7 (2.7) 3.5 ( 2.7 to 9.7).13 and race/ethnicity Men Non-Hispanic white 26.7 (2.7) 24.4 (2.4) 27.7 (3.4) 1.0 ( 7.5 to 9.6).41 Non-Hispanic black 29.1 (3.3) 29.5 (2.9) 30.9 (4.9) 1.8 ( 9.8 to 13.4) NA Mexican American 17.9 (2.6) 17.8 (1.8) 20.6 (3.9) 2.7 ( 6.5 to 11.9) NA Women Non-Hispanic white 25.1 (2.1) 26.8 (2.3) 30.2 (3.1) 5.1 ( 2.2 to 12.4).09 Non-Hispanic black 28.6 (2.7) 35.0 (2.7) 35.8 (4.2) 7.2 ( 2.6 to 17.0) NA Mexican American 16.5 (2.2) 17.9 (2.1) 20.7 (3.4) 4.2 ( 3.8 to 12.2) NA Abbrreviations: CI, confidence interval; NA, not applicable due to unreliable data. *Data are weighted to the US population. P.001 for the difference among racial/ethnic groups, with non-hispanic whites as referent, or for the difference among 3 age groups, with 60 years as referent. P.01 for the difference among racial/ethnic groups, with non-hispanic whites as referent, or for the difference among 3 age groups, with 60 years as referent. Estimates are unreliable because of National Health and Nutrition Examination Survey minimum sample size criteria or coefficient of variation of at least 0.30. Women 18-39 40-59 60 Error bars indicate 95% confidence intervals. Data are weighted to the US population. To address the possibility that the increase in the age-adjusted hypertension prevalence could be secondary to the increase in BMI from 1988-1991 to 1999-2000, we calculated the contribution of this increase in BMI to the increase in hypertension prevalence. Adjusting the 1988-1991 hypertension prevalence for the differences between 1988-1991 and 1999-2000 covariates using analysis of covariance, 2.0% of the 3.6% increase of hypertension prevalence was attributable to an increase in BMI. Because the recommended goal for hypertension control has been changed to less than 130/85 mm Hg in those with diabetes, 18 we considered the possibility that the increase in prevalence in the 1999-2000 phase may be due to initiation of antihypertensive therapy at lower BP levels, in accord with this new recommendation. A separate analysis of age-adjusted prevalence excluding those with diabetes demonstrated an increase in hypertension prevalence between 1988 and 2000, but this increase was no longer significant (24.3 [SE, 2.0] in 1988-1991 vs 27.8 [SE, 1.9] in 1999-2000; P=.10). In 1999-2000, 68.9% of all hypertensive participants were aware of their hypertension, and 58.4% were receiving BP medication (TABLE 5). Hypertension was controlled in 53.1% of those taking medication, and among all hypertensive participants, BP was controlled in only 31.0%. Awareness remained unchanged from 1988 to 2000, although treatment and overall control increased by 6.0% (P=.007) and 6.4% (P=.004), respectively. Among participants with diabetes, control rates declined but not significantly, possibly because of the small number of hypertensive individuals with diabetes. Based on the BP criterion of less than 140/90 mm Hg, 46.9% of all patients with hypertension and diabetes had their hypertension controlled in 1999-2000 compared with 53.1% in 1988-1991. Control rates were lower for participants with diabetes, based on the BP criterion of less than 130/85 mm Hg. We then evaluated the separate effects of sex, race/ethnicity, and age on hypertension awareness, treatment, and control (TABLE 6). Between 1988 and 2000, hypertension awareness rates remained stable in both men and women. Hypertension treatment and control rates increased in men (P.001 for both) but did not change significantly in women. In the 1999-2000 survey, hy- 202 JAMA, July 9, 2003 Vol 290, No. 2 (Reprinted) 2003 American Medical Association. All rights reserved.

pertension awareness was similar between men and women (P =.12), whereas treatment rates were higher, although nonsignificantly (P=.03), and control rates in those being treated were lower (P=.006) in women than in men. Hypertension awareness rates were unchanged and treatment rates improved in all 3 racial/ethnic groups between 1988 and 2000, but the increase was only significant in non-hispanic whites (non- Hispanic whites, P=.009; non-hispanic blacks, P=.02; and Mexican Americans, P =.05). Hypertension control rates improved in non-hispanic whites (P=.01 for treated hypertension and P=.002 for all hypertension); non-hispanic white men demonstrated the highest increase in control rates (P.001) (Table 6). Control rates did not change significantly for Mexican Americans between 1988 and 2000. In the 1999-2000 survey, hypertension awareness (P=.005), treatment (P.001), and overall control rates (P.001) were lower in Mexican Americans than in non-hispanic whites and non-hispanic blacks. Furthermore, rates of hypertension control among those being treated were lower in non- Hispanic blacks than in non-hispanic whites (P=.02) (Table 5). Hypertension awareness did not change significantly from 1988 to 2000 in any age group (TABLE 7). Treatment (P=.01) and control (P=.006 for treated and P.001 for all) improved significantly in those aged 40 to 59 years between 1988 and 2000, whereas only overall control rates improved in those aged 60 years or older (P=.02). Despite similar hypertension awareness and treatment rates, control rates were lower during each of the 3 surveys in participants aged 60 years or older than in those aged 40 to 59 years (P=.03 for 1988-1991 and P.001 for 1999-2000) (Table 7). Hypertension awareness, treatment, and control rates tended to be lowest in participants aged 18 to 39 years in each of the 3 surveys. However, because of the low hypertension prevalence and the high relative SE in this age group, these observations must be interpreted cautiously. FIGURE 2 depicts overall hypertension control rates by age group (excluding those 39 years) and by race/ethnicity for men and women in the 1999-2000 survey. For both sexes and both age groups, Mexican Americans had the lowest rates of hypertension control. In those aged 40 to 59 years, non-hispanic black men and women had lower rates of hypertension control than non-hispanic whites. However, in those aged 60 years or older, hypertension control rates were similar in non-hispanic white and non- Hispanic black men, whereas the rate of hypertension control was lower in non- Hispanic white than in non-hispanic black women aged 60 years or older. COMMENT This analysis indicates that almost 29% of the adult US population, an estimated 58.4 million individuals, had hypertension in 1999-2000. This is an overall increase from 1988-1991 and demonstrates a reversal of the previously reported trend of an overall decline in hypertension prevalence between 1960 and 1991 using the NHANES survey. 4 It also shows that women, non-hispanic blacks, and the older population have the highest rates of hypertension. In 1999-2000, almost 30% of all hypertensive individuals were unaware of their illness, 42% were not being treated, and, at the time that their BP was measured, 69% did not have their hypertension controlled. Women, older participants, and Mexican Americans tended to have the lowest rates of control. In addition, in 1999-2000, nearly 75% of all patients with diabetes and hypertension did not have their hypertension controlled to the BP target of less than 130/85 mm Hg recommended in 1997. 18 Table 4. Multiple Regression Analysis of the Association Between Hypertension Prevalence and Demographic Factors and BMI Regression Coefficient (SE) Factors 1988-1991 1991-1994 1999-2000 Age (per 1-y increase) 1.2 (0.04)* 1.2 (0.03)* 1.3 (0.04)* (referent: women) 3.5 (1.3) 0.03 (0.7) 1.4 (1.5) (referent: Mexican American) Non-Hispanic white 1.1 (0.9) 0.2 (1) 0.6 (1.4) Non-Hispanic black 7.0 (1.4)* 10 (0.1)* 8.2 (1.7)* BMI (per 1 unit of increase) 1.3 (0.07)* 1.3 (0.1)* 1.2 (0.1)* R 2 0.30 0.30 0.31 *P.001 for the independent association between hypertension prevalence and each factor after adjusting for the remaining factors. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Table 5. Awareness, Treatment, and Control Among Participants With Hypertension in the US Population, 1988-2000* Prevalence, % (SE) Change, 1988 to 2000 1988-1991 (n = 3045) 1991-1994 (n = 3017) 1999-2000 (n = 1565) % (95% CI) P Value Awareness 69.2 (1.3) 67.8 (1.8) 68.9 (1.5) 0.3 ( 4.2 to 3.6).58 Treatment 52.4 (1.4) 52.0 (1.0) 58.4 (2.0) 6.0 (1.2 to 10.8).007 Control Among those treated 46.9 (2.2) 43.6 (1.7) 53.1 (2.4) 6.2 (0 to 12.6).03 Among all with hypertension 24.6 (1.4) 22.7 (1.1) 31.0 (2.0) 6.4 (1.6 to 11.2).004 140/90 mm Hg 53.1 (4.5) 41.6 (5.8) 46.9 (4.7) 6.2 ( 19.0 to 6.6).83 (Among treated hypertensive diabetic individuals) 130/85 mm Hg (Among treated hypertensive diabetic individuals) 28.5 (4.2) 17.2 (4.2) 25.4 (4.0) 3.1 ( 14.5 to 8.3).70 Abbreviation: CI, confidence interval. *Data are weighted to the US population. Estimates are unreliable because of National Health and Nutrition Examination Survey minimum sample size criteria or coefficient of variation of at least 0.30. 2003 American Medical Association. All rights reserved. (Reprinted) JAMA, July 9, 2003 Vol 290, No. 2 203

The observed increase in hypertension prevalence during the last 10 years is in accordance with results from the BRFSS. 6 However, as expected, the prevalence based on NHANES data is Table 6. Awareness, Treatment, and Control by and Race/Ethnicity in the US Population, 1988-2000* Prevalence, % (SE) Change, 1988 to 2000 and Race/Ethnicity 1988-1991 1991-1994 1999-2000 % (95% CI) P Value Awareness Men 63.2 (2.2) 60.1 (2.9) 66.3 (2.4) 3.1 ( 3.3 to 9.5).17 Women 75.1 (1.4) 73.6 (1.5) 71.2 (2.2) 3.9 ( 9.0 to 1.2).93 Non-Hispanic white 70.6 (1.4) 67.5 (1.8) 69.5 (2.0) 1.1 ( 5.9 to 3.7).67 Non-Hispanic black 73.3 (1.6) 72.6 (1.6) 73.9 (2.7) 0.6 ( 5.6 to 6.8).42 Mexican American 54.4 (2.3) 62.0 (4.0) 57.8 (3.6) 3.4 ( 5.0 to 11.8).21 Treatment Men 44.5 (1.9) 42.6 (1.8) 54.3 (2.5) 9.8 (7.2 to 23.4).001 Women 60.1 (1.5) 60.0 (1.5) 62.0 (2.3) 1.9 ( 3.5 to 7.3).24 Non-Hispanic white 53.9 (1.6) 51.9 (1.4) 60.1 (2.1) 6.2 (1.0 to 11.4).009 Non-Hispanic black 55.8 (1.7) 56.4 (2.4) 63.0 (2.9) 7.2 (0.6 to 13.8).02 Mexican American 34.1 (1.5) 43.5 (0.2) 40.3 (3.4) 6.2 ( 1.1 to 13.5).05 Control (All Treated) Men 44.6 (2.6) 40.2 (3.7) 59.9 (3.2) 15.3 (7.2 to 23.4).001 Women 48.5 (3.3) 45.7 (2.8) 47.8 (3.0) 0.7 ( 9.4 to 8.0).26 Non-Hispanic white 47.4 (2.5) 43.8 (2.3) 55.6 (2.7) 8.2 (1.0 to 15.4).01 Non-Hispanic black 43.7 (3.0) 41.2 (2.4) 44.6 (3.6) 0.9 ( 8.3 to 10.1).42 Mexican American 40.2 (4.4) 37.5 (1.9) 44.0 (4.7) 3.8 ( 8.8 to 16.4).28 Control (All Hypertensive) Men 19.9 (1.3) 17.2 (1.9) 32.6 (2.4) 12.7 (7.4 to 18.0).001 Women 29.1 (2.3) 27.4 (2.1) 29.6 (2.2) 0.5 ( 5.7 to 6.7).44 Non-Hispanic white 25.6 (1.6) 22.7 (1.5) 33.4 (2.1) 7.8 (2.6 to 13.0).002 Non-Hispanic black 24.4 (1.6) 23.3 (2.0) 28.1 (2.6) 3.7 ( 2.3 to 9.7).11 Mexican American 13.7 (1.3) 16.3 (2.3) 17.7 (2.5) 4.0 ( 1.5 to 9.5) NA and race/ethnicity Men Non-Hispanic white 20.7 (1.5) 17.5 (2.3) 36.5 (3.0) 15.8 (9.3 to 22.3).001 Non-Hispanic black 19.8 (2.6) 15.4 (1.5) 26.5 (3.8) 6.7 ( 2.3 to 15.8) NA Mexican American 10.2 (1.3) 14.9 (3.0) 13.1 (3.0) 2.9 ( 3.5 to 9.2) NA Women Non-Hispanic white 30.3 (2.6) 27.2 (2.6) 30.5 (2.9) 0.2 ( 7.4 to 7.8).48 Non-Hispanic black 28.3 (2.3) 28.8 (2.6) 29.4 (3.7) 1.1 ( 7.4 to 9.6).40 Mexican American 17.9 (2.5) 18.0 (2.8) 22.8 (4.1) 4.9 ( 4.5 to 14.3) NA Abbreviations: CI, confidence interval; NA, not applicable due to unreliable data. *Data are weighted to the US population. Estimates are unreliable because of National Health and Nutrition Examination Survey minimum sample size criteria or coefficient of variation of at least 0.30. P.05 for the difference among groups within the same survey phase (Non-Hispanic whites as the referent for race/ ethnicity). P.01 for the difference among groups within the same survey phase (Non-Hispanic whites as the referent for race/ ethnicity). P.001 for the difference among groups within the same survey phase (Non-Hispanic whites as the referent for race/ethnicity). higher because BP measurement was not performed in the BRFSS survey. Our data suggest that the increased prevalence is not explained by an increased awareness of hypertension. Potentially, the increased prevalence may be related to an increase in BMI as well as the aging of the US population. Based on an analysis of NHANES data, Flegal et al 26 recently reported an increase in prevalence of obesity during this same period. Our analysis indicates that BMI was associated with higher hypertension prevalence after adjusting for age, sex, and race/ethnicity and contributed to 2% more than half of the 3.6% increase in hypertension prevalence. Therefore, the increased prevalence of hypertension between 1988-1991 and 1999-2000 appears to be partially related to but not solely secondary to the increase in BMI. Although awareness rates remained unchanged, treatment and control rates have each increased by approximately 6% between 1988 and 2000. In the latest survey, treatment and control rates of 58% and 31% are comparable with rates observed in the Framingham data between 1990 and 1995, in which 60.7% of hypertensive patients were treated and 29% had their hypertension controlled. 27 Furthermore, our analysis shows that, compared with younger individuals with hypertension, older individuals with hypertension have a lower rate of control despite being equally likely to be treated. Although previous studies have also shown that hypertension is less likely to be controlled in older patients, 27-30 this analysis demonstrates that since 1988 the control rate in the elderly population has minimally increased and remains lower than in those aged 40 to 59 years. We also observed that Mexican Americans had lower rates of awareness, treatment, and control than non-hispanic whites and non- Hispanic blacks. This pattern persisted between 1988 and 2000. Women had a greater increase in hypertension prevalence than men from 1988 to 2000, and in the 1999-2000 survey, hypertension prevalence was higher in women aged 60 years or older than in any other age or sex group. Other surveys have suggested higher prevalence of hypertension in elderly women. For example, in the National Health Interview Survey, 38% of women 65 to 74 years old reported hypertension com- 204 JAMA, July 9, 2003 Vol 290, No. 2 (Reprinted) 2003 American Medical Association. All rights reserved.

pared with 31% of men in the same age group. 31 In the current analysis, despite the increase in hypertension prevalence in women, awareness, treatment, and control rates remained unchanged from 1988 to 2000. Lowering BP in patients with diabetes and hypertension is associated with decreases in cardiovascular events and renal failure. 32,33 Our analysis demonstrates that in 1999-2000, only one quarter of diabetic participants receiving antihypertensive drugs had their hypertension controlled to the recommended BP of less than 130/85 mm Hg. In addition, between 1988 and 2000, the hypertension control rate tended to decline in diabetic participants based on each of the 2 different BP target criteria, although these changes did not reach statistical significance. With the increased prevalence rate of diabetes mellitus observed in this analysis, uncontrolled hypertension with diabetes is an important health problem in the United States. The low control rates observed in this analysis can be explained in part by lack of awareness or treatment. However, even in those who reported that they were receiving hypertension medications, only 53% had hypertension controlled to the recommended target. In addition, recent analysis of the Framingham Heart Study demonstrated that control was only 33.7% at follow-up in a cohort of participants with hypertension that was treated and uncontrolled at baseline. 34 Conceivably, different health insurance coverage may affect different age-related rates of hypertension awareness and control and the effect of age on race/ethnicity and sex differences. However, despite universal health insurance (Medicare) for those aged 65 years or older, hypertension control rates were lowest among individuals aged 60 years or older. Other reports have also noted low hypertension control rates in the elderly, 28 in patients treated at a Veterans Administration hospital, 35 and in inner-city African Americans, 36 despite availability and access to medical care. These observations suggest that improving the health care system to better manage hypertension may improve BP control in the United States. In addition, improving hypertension awareness should result in improved treatment and control rates. Although measurements obtained at a single point in time may overestimate the prevalence of hypertension, this potential problem was minimized by taking the average of 3 separate measurements obtained under the same standardized conditions in each of the surveys. Other potential sources of bias in the reported estimates of hypertension prevalence include possible BP control by nonpharmacological means (diet and exercise), failure to sample homeless or other unnumerated persons, possible differential response rates, and lack of estimates for smaller racial/ethnic groups. Also, this analysis depends on a national survey that documents selfreported medical history. Although this method has been shown to be accurate in estimating hypertension preva- Table 7. Awareness, Treatment, and Control by Age in the US Population, 1988-2000* Figure 2. Overall Hypertension Control Rates in 1999-2000 by Age and Race/Ethnicity in Men and Women Control Rate, % 70 60 50 40 30 20 10 0 Prevalence, % (SE) Change 1988 to 2000 1988-1991 1991-1994 1999-2000 % (95% CI) P Value Awareness 18-39 61.5 (4.5) 49.1 (6.9) 51.8 (5.8) 9.7 ( 24.1 to 4.7) NA 40-59 73.2 (2.4) 72.7 (3.3) 73.3 (2.8) 0.1 ( 7.1 to 7.3).49 60 68.3 (1.3) 69.1 (1.6) 69.8 (1.9) 1.5 ( 3.0 to 6.0).26 Treatment 18-39 34.1 (5.4) 24.8 (3.5) 27.7 (5.3) 6.4 ( 21.2 to 8.4) NA 40-59 53.9 (2.7) 54.2 (2.4) 62.9 (3.1) 9.0 (0.9 to 17.1).01 60 55.1 (1.2) 56.7 (1.6) 62.7 (2.0) 7.6 ( 4.5 to 10.3).006 Control (All Treated) 18-39 61.5 (7.2) 70.2 (7.4) 51.9 (11.5) 9.6 ( 36.2 to 17.0) NA 40-59 53.7 (3.4) 54.2 (3.6) 66.4 (3.7) 12.7 (2.9 to 22.5).006 60 40.8 (2.8) 35.2 (2.2) 43.7 (2.5) 2.9 ( 4.5 to 10.3).22 Control (All Hypertensive) 18-39 21.0 (5.2) 17.4 (3.1) 14.4 (4.3) 6.6 ( 19.8 to 6.6) NA 40-59 28.9 (2.4) 29.4 (2.4) 41.6 (3.2) 12.7 (4.9 to 20.5).001 60 22.5 (1.7) 20.0 (1.6) 27.4 (1.8) 4.9 (0 to 9.8).02 Abbreviations: CI, confidence interval; NA, not applicable due to unreliable data. *Data are weighted to the US population. Estimates are unreliable because of National Health and Nutrition Examination Survey minimum sample size criteria or coefficient of variation of at least 0.30. P.01 for the difference among groups within the same survey (age 60 years as the referent). P.001 for the difference among groups within the same survey (age 60 years as the referent). Men 40-59 60 Women Non-Hispanic White Non-Hispanic Black Mexican American 40-59 60 Error bars indicate 95% confidence intervals. Data are weighted to the US population. For comparisons between racial/ethnic groups (with non-hispanic whites as the referent), P values are as follows: for Mexican Americans, men aged 40 to 59 years, P.001, men aged at least 60 years, P=.003, women aged 40 to 59 years, P=.002, and women aged at least 60 years, P=.04; for non-hispanic blacks, men aged 40 to 59 years, P=.02, men aged at least 60 years, P=.51, women aged 40 to 59 years, P=.003, and women aged at least 60 years, P=.98. 2003 American Medical Association. All rights reserved. (Reprinted) JAMA, July 9, 2003 Vol 290, No. 2 205

lence, 37 limitations exist. Participants who report inaccurately that they are not receiving antihypertensive medications or who cannot recall if their physician has ever told them that they have hypertension are considered nonhypertensive or unaware of their disease. Also, participants who have been told that they have hypertension but are not receiving medications and have BP below the 140/90 mm Hg cut points are not counted as hypertensive. In addition, in this survey, medication use or type was not confirmed, which can lead to misclassification. For example, participants may have been using medications that lower BP for another indication. Despite progress in treatment and control, hypertension remains an important public health problem, and our analysis of the NHANES data has significant public health implications. The increase in hypertension prevalence in women, non-hispanic blacks, and older individuals highlights the need for interventions that would target prevention in these groups. Even greater strides will need to be made, as the importance of reducing BP with healthy lifestyle interventions in prehypertensive individuals in the general population (BP of 120-129/80-89 mm Hg) has recently been emphasized, and the target BP goal for antihypertensive therapy in diabetic individuals has been lowered to less than 130/80 mm Hg. 38 In addition, improving hypertension treatment and control in women, the older population, Mexican Americans, and diabetic individuals will have a significant impact on overall control rates, which would be translated into improved cardiovascular outcomes. Although control rates have improved since 1988, these rates remain unacceptably low. If the increase in hypertension control rates remains at the current pace, the 50% target for hypertension control by 2010 will not be met. Programs targeting hypertension prevention to achieve the 16% target for hypertension prevalence by 2010 and improving awareness and treatment are of utmost importance for the health of the US population. Author Contributions: Study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content: Hajjar, Kotchen. Acquisition of data, drafting of the manuscript, and statistical expertise: Hajjar. Funding/Support: NHANES was conducted and funded by the National Center for Health Statistics. This analysis was supported by the Division of Geriatrics at Palmetto Health Richland and University of South Carolina/ South Carolina Consortium for Geriatrics. Acknowledgment: We are grateful to Raymond Hoffmann, PhD, Medical College of Wisconsin, for providing advice about statistical analyses. REFERENCES 1. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res. 1995;18:181-196. 2. Himmelmann A, Hedner T, Hansson L, et al. Isolated systolic hypertension: an important cardiovascular risk factor. Blood Press. 1998;7:197-207. 3. Kannel WB. Hypertension as a risk factor for cardiac events epidemiologic results of long-term studies. J Cardiovasc Pharmacol. 1993;21(suppl 2):S27-S37. 4. Burt VL, Cutler JA, Higgoins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the Health Examination Surveys, 1960-1991. Hypertension. 1995;26:60-69. 5. Goff DC, Howard G, Russell GB, Labarthe DR. Birth cohort evidence of population influences on blood pressure in the United States, 1887-1994. Ann Epidemiol. 2001;11:271-9. 6. Ayla C, Greenlund KJ, Croft JB, et al. State-specific trends in self-reported blood pressure screening and high blood pressure United States, 1991-1999. MMWR Morb Mortal Wkly Rep. 2002;51:456-460. 7. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension. Lancet. 1998; 351:1755-1762. 8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991; 265:3255-3264. 9. Neal B, MacMahon S, Chapman N, for the Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet. 2000;356: 1955-1964. 10. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25:305-313. 11. Healthy People 2000: Midcourse Review and 1995 Revisons. Washington, DC: US Government Printing Office; 1995. 12. US Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. 2nd ed. Washington, DC: US Government Printing Office; November 2000. 13. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Vital Health Stat 1. July 1994:1-407. 14. NHANES 1999-2000 public data release file documentation. Available at: http://www.cdc.gov/nchs /data/nhanes/gendoc.pdf. Accessed October 5, 2002. 15. NHANES 1999-2000 addendum to the NHANES- III analytic guidelines. Updated August 30, 2002. Available at: http://www.cdc.gov/nchs/data/nhanes /guidelines1.pdf. Accessed September 15, 2002. 16. National Health and Nutrition Examination Survey III, cycle 2: blood pressure quality control program. Rockville, Md: Westat Inc; 1989. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs /manuals/bpqc.pdf. Accessed September 15, 2002. 17. Blood pressure section of the physician examination, NHANES 1999-2000. June 2002. Available at: http: //www.cdc.gov/nchs/about/major/nhanes /NHANES99_00.htm. Accessed July 16, 2002. 18. Sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-2442. 19. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2. September 1992:1-35. 20. National Health and Nutrition Examination Survey III: Weighting and Estimation Methodology. Rockville, Md: Westat Inc; 1996. 21. Rust KF, Rao JN. Variance estimation for complex survey data using replicate methods. Stat Med Res. 1996;5:283-310. 22. Rust KF. Variance estimation for complex estimators in sample surveys. J Off Stat. 1985;1:381-397. 23. Berglund PA. Analysis of complex sample survey data using the SURVEYMEANS and SURVEYREG procedures and macro coding. In: Proceedings of the Twenty-Seventh Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 2002. 24. Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES III (1988-94). October 1996. Available at: http: //www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom /nchs/manuals/nh3guide.pdf. Accessed July 2002. 25. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected US population. Healthy People 2010 Stat Notes. January 2001:1-10. 26. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727. 27. Lloyd DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure. Hypertension. 2000;36:594-599. 28. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486. 29. Barker WH, Mullooly JP, Linton KL. Trends in hypertension prevalence, treatment, and control in a welldefined older population. Hypertension. 1998;31(1 pt 2):552-559. 30. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women s Health Initiative. Hypertension. 2000;36:780-789. 31. Hypertension: A Common Condition for Older Americans. Washington, DC: National Academy on an Aging Society; 2000. 32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713. 33. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes. 2001; 50:843-850. 34. Lloyd-Jones DM, Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community. Hypertension. 2002;40:640-646. 35. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-1963. 36. Kotchen JM, Shakoor-Abdullah B, Walker WE, Chelius TH, Hoffmann RG, Kotchen TA. Hypertension control and access to medical care in the inner city. Am J Public Health. 1998;88:1696-1699. 37. Vargas CM, Burt VL, Gillum RF, Pamuk ER. Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988-1991. Prev Med. 1997;26(5 pt 1):678-685. 38. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA. 2003;289: 2560-2571. 206 JAMA, July 9, 2003 Vol 290, No. 2 (Reprinted) 2003 American Medical Association. All rights reserved.